CGRP migraine drugs ready to battle for market share

30 September 2019

headache_migraine_credit_depositphotos_large

Analysts and crystal ball gazers in pharma love nothing more than a battle for dominance in a major market.

The scrap for sales over statins from 20 years ago, and the competition over the first wave of immuno-oncology drugs from the last five years, are examples of rival big pharma companies tussling to ensure their product is the leader of a new approach to tackling a disease.

One of the most fascinating such battles that has been bubbling up is over the migraine space – a market predicted by GlobalData to be worth nearly $9 billion by 2026.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK